Abiraterone acetate for the treatment of prostate cancer (Q38063964)

28 August 2017

1 reference

title

Abiraterone acetate for the treatment of prostate cancer (English)

1 reference

28 August 2017

Charles J Ryan

1

1 reference

28 August 2017

Michael L Cheng

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

30 November 2012

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

91-96

1 reference

28 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Ras signaling in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Contribution of the androgen receptor to prostate cancer predisposition and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

Flushing oral oncology drugs down the toilet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.745852

10.1517/14656566.2013.745852

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference